Overexpression of the anti-apoptotic Bcl-2 family proteins occurs commonly in human cancers. Bfl-1 is highly expressed in some types of malignant cells, contributing significantly to tumor cell survival and chemoresistance. Therefore, it would be desirable to have chemical antagonists of Bfl-1. To this end, we devised a fluorescence polarization assay (FPA) using Bfl-1 protein and fluorescein-conjugated Bid BH3 peptide, which was employed for high-throughput screening of chemical libraries. Approximately 66 000 compounds were screened for the ability to inhibit BH3 peptide binding to Bfl-1, yielding 14 reproducible hits with ≥50% displacement. After dose-response analysis and confirmation using a secondary assay based on time-resolved fluorescence resonance energy transfer (TR-FRET), two groups of Bfl-1-specific inhibitors were identified, including chloromaleimide and sulfonylpyrimidine series compounds. FPAs generated for each of the six anti-apoptotic Bcl-2 proteins demonstrated selective binding of both classes of compounds to Bfl-1. Analogs of the sulfonylpyrimidine series were synthesized and compared with the original hit for Bfl-1 binding by both FPAs and TR-FRET assays. The resulting structure-activity relation analysis led to the chemical probe compound CID-2980973 (ML042). Collectively, these findings demonstrate the feasibility of using the HTS assay for discovery of selective chemical inhibitors of Bfl-1.
Introduction
The mitochondrial pathway for cell death is governed by members of the Bcl-2 family proteins. Several homologs of Bcl-2 have been identified, with some functioning as blockers and others as promoters of cell death, constituting a family of more than 27 genes in humans. [1] [2] [3] Anti-apoptotic Bcl-2 family proteins (Bcl-2, Bcl-X L , Bcl-W, Bcl-B, Mcl-1, and Bfl-1) interact with BH3-only pro-apoptotic members (e.g., Bid, Bad, Bim, Puma, Noxa, Hrk, Bmf, Nbk/Bik) to regulate pro-apoptotic multidomain Bcl-2 family proteins Bax and Bak, which trigger mitochondrial outer membrane permeability and release of cytochrome c and other pro-apoptotic factors that promote activation of caspases, causing apoptosis. 1, 3, 4 The human genome contains six genes that encode antiapoptotic members of the Bcl-2 family. 2 Among these is Bfl-1 (also known as A1 in mice), a nuclear factor-κB (NF-κB)-inducible member of the Bcl-2 family. [5] [6] [7] [8] [9] Bfl-1 promotes the survival of immune and inflammatory cells, including mast cells associated with allergy. 10 Given that transgenic overexpression of various anti-apoptotic Bcl-2 family proteins in lymphocytes causes autoimmunity, 11, 12 Bfl-1 may represent a target for certain autoimmune and allergic diseases. In addition, Bfl-1 is highly upregulated in therapy-resistant B-cell chronic lymphocytic leukemia (B-CLL), acute myelogenous leukemia with poor prognosis, large B-cell lymphomas, and some other cancers. 7, 8, 13 Bfl-1 appears to play a critical role in tumor cell survival and chemoresistance, as demonstrated by the observation that Bfl-1 knockdown by short-hairpin RNA (shRNA) can restore apoptosis of drug-resistant leukemia and lymphoma cells in culture, [14] [15] [16] thus suggesting the importance of Bfl-1 as a therapeutic target for cancer. Bfl-1 has also been shown to be responsible for resistance of malignant cells to chemical inhibitors that neutralize other members of the Bcl-2 family, implying that inhibition of Bcl-2 and Bcl-X L can be insufficient to achieve apoptosis when Bfl-1 is highly expressed. 14, [16] [17] [18] Synthetic BH3 peptides bind anti-apoptotic Bcl-2 family proteins with nanomolar affinities, promoting apoptosis. 19, 20 Nonpeptidyl compounds have been identified that compete with BH3 peptides for binding to anti-apoptotic Bcl-2 family proteins, mimicking BH3 peptides and creating interest in development of these molecules as potential cancer therapeutics. 21, 22 Of note, systematic analysis of all chemical inhibitors of Bcl-2 thus far described in the literature reveals that few of the synthetic compounds or natural products previously reported bind Bfl-1 with a biologically relevant affinity, 21 and none binds selectively to Bfl-1. Thus, the pocket on Bfl-1 that binds BH3 peptides is presumably sufficiently different from other Bcl-2 family members that it should be possible to obtain selective inhibitors, either directly from screens of diverse libraries or secondarily through chemical analoging of hits that interact with Bfl-1.
To this end, we have devised a homogeneous fluorescence polarization assay (FPA) based on binding of recombinant soluble Bfl-1 protein to synthetic Bid BH3 peptide conjugated with a fluorochrome. In this assay, the rotation of fluorochrome-conjugated peptide ligand is slowed upon binding the Bfl-1 target protein, thus affecting the interaction of the fluorochrome with polarized light. Highthroughput conditions were optimized, and approximately 66 000 chemical compounds were screened as proof of concept. The primary hits were further confirmed using a timeresolved fluorescence resonance energy transfer (TR-FRET) assay. We succeeded in obtaining two groups of Bfl-1specific inhibitors, including a chloromaleimide series that has been described previously 23 and a sulfonylpyrimidine series described here. The active sulfonylpyrimidines were demonstrated to bind selectively to Bfl-1 among the six anti-apoptotic Bcl-2 family proteins. Despite the general challenges of identifying inhibitors of protein-protein interactions by high-throughput screening (HTS) and the length of BH3 peptides (~16 amino acids), these findings demonstrate the feasibility of using the FPA reported here for identification of compounds that interact competitively with the BH3 binding site on Bfl-1, which may serve as a starting point for optimization and eventual generation of drug candidates.
Materials and Methods

Protein Purification
His 6 -"truncated" Bid (t-Bid) was prepared as previously reported. 24 Glutathione S-transferase (GST)-tagged proteins containing Bcl-X L , Bcl-2, Bcl-W, Bcl-B, Bfl-1, and Mcl-1 lacking their C-terminal transmembrane domains (~ last 20 amino acids) ("ΔTM") were expressed from the pGEX 4T-1 plasmid in XL-1 Blue cells (Stratagene, La Jolla, CA) as previously reported. 25 Briefly, cells were grown in 2 L of LB with 50 µg/mL ampicillin at 37 °C to an optical density (OD) 600 nm of 1.0, then isopropyl-β-Dthiogalactopyranoside (IPTG; 0.5 mM) was added, and the cultures were incubated at 25 °C for 6 h. Cells were then recovered in 20 mM phosphate buffer (pH 7.4), 150 mM NaCl, 1 mM dithiothreitol (DTT), 1 mM EDTA, and 1 mM phenylmethylsulfonyl fluoride (PMSF), followed by sonication. Cellular debris was sedimented by centrifugation at 25 000 g for 20 min, and the resulting supernatants were incubated with 10 mL of glutathionine-Sepharose (Amersham Biosciences, Piscataway, NJ) at 4 °C for 2 h. The resin was washed three times with 20 mM phosphate buffer (pH 7.4), 150 mM NaCl, and 1 mM DTT, and then 10 mM of reduced glutathione dissolved in 50 mM Tris-HCl (pH 8.0) was used to elute the GST fusion proteins.
Fluorescence Polarization Assays
FPAs were performed as described previously using various Bcl-2 family proteins and fluorescein isothiocyanate (FITC)-conjugated Bid BH3 peptide. 25 Briefly, Bfl-1 proteins were incubated in 384-well black round-bottom plates with 5 or 2.2 nM FITC-Bid BH3 peptide (FITC-Ahx-EDIIRNIARHLAQVGDSMDR) in a total volume of 20 µL in the dark. Fluorescence polarization was measured using a LJL Analyst HT plate reader (Molecular Devices Corp., Sunnyvale, CA) in phosphate-buffered saline (PBS) or 25 mM Bis-Tris buffer containing 1 mM of TECP, 0.005% Tween-20 (pH 7.0). IC 50 determinations were performed using a sigmoidal dose-response nonlinear regression model (Y = Bottom + (Top -Bottom)/1 + 10 (LogEC50 -X)*Hill slope ) with GraphPad Prism software (GraphPad, Inc., San Diego, CA).
High-Throughput Screening
Approximately 66 000 compounds (10 mM stock solution in DMSO) from the National Institutes of Health (NIH) Small Molecule library were plated into black, 384-well, round-bottom plates (Greiner Bio-One, Frickenhausen, Germany) using a BioMek FX Laboratory Automation Workstation (Beckman Coulter, Fullerton, CA). The ThermoScientific Matrix WellMate bulk dispenser (Thermo Fisher Scientific, Hudson, NH) was then used to add GST-Bfl-1, followed by FITC-Bid BH3 peptide, both diluted in 25 mM Bis-Tris, 1 mM TCEP, 0.005% Tween-20 (pH 7.0). The first column of the screening plate was positive controls (16 wells), and the second column of the plate was negative controls (16 wells). The remaining wells contained ~20 µM compound, 3 nM GST-Bfl-1, and 2.2 nM FITC-Bid BH3 peptide in a total volume of 20 µL. After a 4-h incubation at room temperature in the dark, fluorescence polarization was measured using an Analyst HT Multi-Mode Plate Reader (Molecular Devices), with an excitation filter at 485 nM and an emission filter at 530 nM. Data analysis was performed using CBIS software (ChemInnovation Software Inc, San Diego, CA).
Competitive Peptide Displacement Assays for Assessing Compound Selectivity
Methods for competitive peptide displacement assays were similar to previous publications. 25 Briefly, empirically optimized amounts of various GST fusion proteins (3 nM for Bfl-1; 20 nM for Bcl-2, Bcl-X L , Bcl-W, and Bcl-B; and 10 nM for Mcl-1) were incubated with the compounds at various concentrations for 5 min at room temperature in 25 mM Bis-Tris, 1 mM TCEP, 0.005% Tween-20 (pH 7.0). Then, 2.2 nM FITC-Bid (for Bfl-1), 10 nM FITC-Bim (for Bcl-2, Bcl-X L , Bcl-W, and Bcl-B), or 5 nM FITC-Bak (for Mcl-1) BH3 peptide was added, resulting in a total volume of 20 µL per well. DMSO concentration (resulting from compound addition) did not exceed 0.2% (vol:vol). Fluorescence polarization was measured after 20 min. IC 50 determinations were generated by fitting the experimental data using a sigmoidal dose-response nonlinear regression model with GraphPad Prism software (GraphPad, Inc.).
Time-Resolved Fluorescence Resonance Energy Transfer Assays
For TR-FRET assays, GST-Bfl-1 and anti-GST-terbium (Invitrogen, Carlsbad, CA) were mixed together with the FITC-Bid BH3 peptide in 20 mM Bis-Tris containing 0.005% Tween-20 in 384-well plates in a total volume of 20 µL per well. After incubation at room temperature for 10 min, 2 µL of compound-containing solutions was added to the reaction mixtures containing 3 nM Bfl-1, 2.2 nM FITC-Bid BH3 peptide, and 2 nM anti-GST-terbium for 30 min at room temperature. TR-FRET signals were measured with a SpectraMax M5 plate reader (Molecular Devices) using the following settings: excitation at 330 nm, emission for FITC signal at 490 nm, and emission for terbium signal at 520 nm. IC 50 determinations were generated by fitting the experimental data using a sigmoidal doseresponse nonlinear regression model with GraphPad Prism software (GraphPad, Inc.).
Mitochondria Purification and Protein Release Assays
HeLa cells were pelleted by centrifugation and then washed once in HM buffer (10 mM HEPES [pH 7.4], 250 mM mannitol, 10 mM KCl, 5 mM MgCl 2 , 1 mM EGTA), containing 1 mM PMSF and a mixture of protease inhibitors (Roche Molecular Biochemicals, Indianapolis, IN). The cell pellet was then homogenized in HM buffer by 60 strokes of a dounce homogenizer, using a B-type pestle. The homogenate was centrifuged twice at 600 g for 5 min to remove nuclei and debris. The resulting supernatant was centrifuged at 10 000 g for 10 min, and the resulting mitochondria-containing pellet was washed twice with HM buffer.
For mitochondrial protein release assays, 10 µL of mitochondria (50 µg) was added to a final volume of 50 µL HM buffer containing compounds, with or without t-Bid or Bcl-2 family proteins, at 30 °C for 15 min. The reactions were further incubated at 30 °C for 40 to 60 min, and then mitochondria were pelleted by centrifugation and the supernatants were collected, boiled in Laemmli sample buffer, and analyzed by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE)/immunoblotting using anti-SMAC antibody. 26 Compound Synthesis CID 1151859 (MLS-0009480). A mixture of 4,4,4-trifluoro-1-phenylbutane-1,3-dione (216 mg, 1.0 mmol) and ethyl 2-(carbamimidoylthio)acetate (194 mg, 1.2 mmol) in ethanol (10 mL) was placed in a sealed tube and heated at 100 °C for 5 h. The resulting solution was cooled and reduced to dryness via rotary evaporation, and the residue was purified via silica gel chromatography (EtOAc:hexanes) to yield the pyrimidine intermediate, ethyl 2-((4-phenyl-6-(trifluoromethyl)pyrimidin-2-yl)thio)acetate. To this product (0.17 mg, 0.5 mmol) was added mCPBA (230 mg, 1.0 mmol, 77% by weight) in 5 mL of dichloromethane (DCM), and the resulting mixture was stirred at room temperature for 20 h. The mixture was diluted with DCM and extracted with water and brine. The organic layer was collected and the excess DCM was removed by rotary evaporation. The product was isolated by reverse-phase preparative high-performance liquid chromatography (HPLC; H 2 O:ACN). 1 
Results
Development of Bfl-1 Fluorescence Polarization Assays
We previously reported a nonoptimized FPA for Bfl-1 that proved suitable for characterizing known inhibitors of Bcl-2 family proteins. 25 This FPA that measures binding of GST-Bfl-1 protein to FITC-conjugated Bid BH3 peptide in PBS without detergents was further optimized for HTS applications. To this end, various buffer, salt concentrations, and detergent conditions were explored. Using a modified Bis-Tris buffer, we achieved a 30% increase in the assay window (signal-to-noise ratio), 3-fold relative to the K d , allowing a 33-fold reduction of protein concentration and an improvement in the signal stability from 15 min to 24 h compared to PBS buffer without detergent ( Fig. 1A,1B , data not shown). In the optimized FPAs, the concentration of Bfl-1 is approximately equivalent to the dissociation constant (K d = 9.2 ± 0.2 nM) of its complex with the fluorescent BH3 peptide ligand. Similarly, a TR-FRET assay was optimized using the same modified Bis-Tris buffer ( Fig. 1C ; K d = 2.9 ± 0.3 nM). In addition to decreasing the assay protein requirements, the optimized conditions also improved assay sensitivity. We note that our experience has been that each batch of recombinant Bfl-1 protein should be tested and protein concentration adjusted as shown in Figure 1A .
Another issue observed during assay optimization was a time-dependent Bfl-1 binding to the fluorescent probe. To compensate for this phenomenon, we reformatted the assay to include a 1-h incubation of Bfl-1 in the presence of compounds and a 4-h incubation after the subsequent addition of the fluorescent probe (FITC-BH3 peptide).
Previously, we observed that the binding characteristics of the GST fusion Bfl-1 protein is similar to untagged Bfl-1 in BH3 peptide binding assays. 26 Thus, for convenience, we choose GST fusion Bfl-1 protein for conducting a proof-ofconcept HTS campaign. 
High-Throughput Screening
The performance of the optimized assay was evaluated by performing multiple replicate tests in a 384-well format using either FITC-Bid BH3 peptide alone (assay minimum) or with Bfl-1 protein (assay maximum). The assay demonstrated robust performance, with a Z′ factor of 0.83 ( Fig. 2A) . Moreover, the Z′ factor remained >0.7 after overnight incubation (data not shown).
The assay was screened against the entire NIH small-molecule library, which at the time consisted of ~66,000 compounds, searching for chemical inhibitors that displaced FITC-Bid BH3 peptide from GST-Bfl-1 protein, resulting in 44 primary positive results, with an average Z′ factor of ~0.75 ± 0.04 (Fig. 2B) . "Hits" were defined as compounds that induced a ≥50% decrease in fluorescence polarization without increasing fluorescence intensity by ≥25% (thus eliminating compounds that interfered with the assay due to their autofluorescence). After correcting for fluorescence interferences, the primary screen then yielded 20 hits. These hits were cherry picked from assay plates and retested, resulting in 14 confirmed hits, representing a hit rate of 0.021%.
A TR-FRET secondary assay used the same molecular interaction between the FITC-Bid BH3 peptide and the GST-Bfl-1 protein, except terbium-conjugated anti-GST served as the fluorescent donor for exciting the FITC BH3 peptide. Of 20 compounds active in the primary FPA-based screen, 14 demonstrated inhibitory activity in the TR-FRET assay. These were the same 14 compounds that showed reproducible activity in the FPA (above).
Compound dose-response curves were generated using both fluorescence polarization (FP) and TR-FRET assays for the 14 validated hits. Compounds that did not display a sigmoidal dose-response curve or that increased fluorescence intensity (some compounds increased fluorescence intensity at concentrations higher than the screening concentration) were eliminated. Finally, seven compounds appeared to be promising based on dose-response results from both the FP and TR-FRET assays (IC 50 values summarized in Table 1 ). The potency of these screening hits varied, with IC 50 values as low as <1 µM to as high as approximately 30 µM, depending on whether measured by FPA or TR-FRET. 
Characterization of Compound Selectivity for Bfl-1
The seven validated hits from the screening could be divided into three groups based on structural features of the compounds: #1 (MLS-0053105 = CID-1180676) is a chloromaleimide, #2 to #5 (#2, MLS-0047123 = CID-2980973; #3, MLS-0009480 = CID-1151859; #4, MLS-0051609 = CID-3244140; #5, MLS-0051509 = CID-3237441) comprise a sulfonylpyrimidine series; and #6 and #7 MLS-0019296 (CID-5389865) and MLS-0025736 (CID-8423532) are quinolinyl-oxadiazoles. The reactivity of these compounds with other targets previously screened and deposited into the PubChem database at the time of our discovery revealed that the chloromaleimide showed reactivity in only 1 of 30 assays tested, the sulfonylpyrimidines in 3 of 60 assays, and the quinolinyl-oxadiazoles in none of 29 assays tested. Thus, these three chemical series do not show promiscuous activity with other classes of targets.
To test compound selectivity against all six human antiapoptotic Bcl-2 family protein members, we established FPAs that monitor the binding of various fluorochromeconjugated BH3 peptides to the recombinant GST fusion proteins. BH3 peptides were selected based on our prior comparison of binding affinities, 27 resulting in pairings for the binding assays as follows: Bfl-1/FITC-Bid BH3 peptide, Bcl-W/FITC-Bim BH3 peptide, Bcl-2/FITC-Bim BH3 peptide, Bcl-X L /FITC-Bim BH3 peptide, and Mcl-1/ FITC-Bak BH3 peptide. Table 2 summarizes the IC 50 values of seven validated compounds for each of the six antiapoptotic Bcl-2 family members. The chloromaleimide compounds showed submicromolar inhibition of Bfl-1, with over 10 times less potent inhibition of Bcl-W, Bcl-2, and Bcl-X L and no activity against Bcl-B and Mcl-1, indicating good selectivity for Bfl-1. The sulfonylpyrimidine compounds showed superb selectivity against Bfl-1, with no inhibition of other Bcl-2 family members at concentrations as high as 100 µM. One of the quinolinyl-oxadiazole series compounds showed cross-reactivity with Bcl-W, but otherwise this series was also Bfl-1 selective ( Table 2) .
Bioactivity of Compounds Tested Using Mitochondrial Assay
Isolated mitochondria were used to test the bioactivity of compounds under circumstances where recombinant Bfl-1 protein nullifies mitochondrial release of proteins induced by t-Bid protein, similar to our previous report where we analyzed BH3 peptide activity. 26 Interestingly, sulfonylpyrimidine CID-1151859 caused mitochondria release of SMAC protein in a concentration-dependent manner (Fig. 3A) , perhaps reflecting activity against endogenous proteins associated with the mitochondria. Recombinant Bfl-1 protein, but not Bcl-2 or Bcl-X L , blocked the release of SMAC protein induced by this compound, consistent with our data indicating selective binding to Bfl-1 (Fig. 3B,3C) . In contrast, chloromaleimide compound CID-1180676 did not cause SMAC release from mitochondria (Fig. 3D) . We then employed recombinant Bid (t-Bid) protein as an inducer of SMAC release from mitochondria and tested the effects of compounds with respect to neutralization by recombinant anti-apoptotic Bcl-2 proteins Bfl-1 and Bcl-X L .
The chloromaleimide compound CID-1180676 negated Bfl-1 protection against t-Bid-induced release of SMAC Various concentrations of compounds were mixed with anti-apoptotic Bcl-2 family proteins (Bfl-1, Bcl-W, Bcl-2, Bcl-XL, Bcl-B, Mcl-1). FITC-BH3 peptides (Bid, Bim, or Bak as indicated) were then added and fluorescence polarization was measured after 30 min. IC 50 determinations were generated by fitting the experimental data using a sigmoidal dose-response. Data are the mean of four determinations (standard derivations ≤15%). from isolated mitochondria, whereas Bcl-X L did not, suggesting selectivity for Bfl-1 (Fig. 3E) .
Structure-Activity Relation Analysis of Chemical Inhibitors of Bfl-1
During the course of this project, more than 180 analogs of the chloromaleimide and sulfonylpyrimidine class compounds were purchased or synthesized, comparing their activity against Bfl-1 using both the FPA and a TR-FRET assay. The structure-activity relation (SAR) analysis of the chloromaleimide series was published recently. 23 Here we describe a brief SAR analysis of the sulfonylpyrimidines (n = 11 compounds tested). Table 3 summarizes the IC 50 values of the compounds. Altogether, the activity of the compounds tested against Bfl-1 varied by as much as approximately one log, ranging from 2.6 µM to 25.1 µM in IC 50 values. The synthetic chemistry strategy employed to follow up on hit compound CID-1151859 is shown in scheme 1 (Fig. 4) . Specifically, 1,3-diketones were reacted with S-substituted carbamimidothioates to afford the corresponding S-alkylpyrimidines. Oxidation of these products at 25 °C with mCPBA furnishes the desired sulfonylpyrimidine Table 3 . Structure-Activity Relation of Sulfonylpyrimidine Analogs Compound competition with BH3 peptide binding to Bfl-1 was measured as in Table 1 . Data from fluorescence polarization assay (FPA) and timeresolved fluorescence resonance energy transfer (TR-FRET) are the mean of three determinations (with standard deviation <15%). analogs. We synthesized and tested a series of compounds, and in vitro data were generated to provide SAR data on the hit series. Initial studies focused on analogs in which the phenyl ring and/or the sulfone substituent were modified, and some of these compounds are shown in Table 3 .
Bfl-1 FP Bfl-1 TR-FRET
For example, a 3-methoxy substituent is tolerated (MLS-0066988 = CID-751044), whereas a 3,4-dimethoxy derivative (MLS-0051609 = CID-3244140) is less potent than the parent molecule. It also appears that replacement of the phenyl ring with a heteroaryl moiety such as furan (MLS-0050257 = CID-3237865) or thiophene (MLS-0041503 = CID-655335 and MLS-0051774 = CID-3245258) is viable. Truncating the sulfonyl side chain to a methylsulfone moiety as in MLS-0066988 (CID-751044), MLS-0050257 (CID-3237865), MLS-0051609 (CID-3244140), and MLS-0051774 (CID-3245258) appears to lead to a modest reduction in potency compared with the lead compound. Homologation of the carbethoxymethylene side chain to the carbethoxyethylene variant (MLS-0046458 = CID-2219262) leads to a slight reduction in potency. More pronounced increases in side chain length, as in compounds MLS-0041503 (CID-655335), MLS-0039077 (CID-2037235), MLS-0050749 (CID-3238559), and MLS-0008909 (CID-654688) leads to further reduction in potency. Ultimately, we selected the 4-fluorophenyl derivative CID-2980973, which is twice as potent as the best hit compound CID-1151859 as the Bfl-1 sulfonylpyrimidine series chemical probe, which has received the designation (http://mli.nih.gov/mli/mlp-probes/?dl_id=1289, ML042 = CID-2980973) from the NIH Molecular Libraries Initiative.
Discussion
Bcl-2 family proteins have been implicated in several diseases. Bfl-1 (known as A1 in the mouse) is an NF-κBinducible anti-apoptotic member of the Bcl-2 family, which has been implicated in cancer and allergic diseases. With respect to cancer, defective apoptosis is a hallmark of many human tumors and is frequently responsible for resistance to therapy. Transcriptome profiling of diffuse large B-cell lymphomas (a common type of non-Hodgkin lymphoma) identified Bfl-1 as a gene signature associated with chemoresistance. 15 Short-hairpin RNAs targeting Bfl-1 mRNAs induce apoptosis of certain lymphoblastoid B-cell lines and diffuse large B-cell lymphoma cell lines. 15 Thus, selective inhibitors of Bfl-1 could find applications for certain lymphomas or lymphoid leukemias, most likely those where constitutively high NF-κB activity or overexpression of Bfl-1 is observed.
Novel small molecules that target Bcl-2 family proteins are now in clinical trials. ABT737 and its orally available derivative ABT263 are the best characterized and show selective and potent activity against Bcl-2, Bcl-X L , and Bcl-W, but not Bcl-B, Mcl-1, and Bfl-1. 21, 28, 29 Although impressive single-agent responses to ABT737 or ABT263 have been reported in early clinical trials for some types of malignancy, 28,29 many tumor cell lines in vitro and most types of solid tumors in patients show resistance to these compounds. 17, 18, 21, 29 The failure of tumor and leukemia cell lines to undergo apoptosis in response to ABT737 or ABT263 in culture has been convincingly attributed, in several cases, to concomitant expression of other members of the Bcl-2 family not targeted by these compounds, including Bfl-1 in some instances. 18, 21 In this scenario, Bfl-1selective compounds could serve as a complement to selective chemical inhibitors of Bcl-2/Bcl-X L such as ABT737/ABT263 for cancer treatment.
With respect to allergic diseases, expression of Bfl-1 is observed in mast cells in vivo and induced in cultured mast cells upon ligation of IgE bound to cell surface Fc receptors. 10 Various gene silencing experiments have suggested that Bfl-1 is required for survival of mast cells following IgE cross-linking, preventing "activation-induced cell death." 10, 30 Thus, compounds targeting Bfl-1 may find utility for certain allergic diseases.
Bfl-1 is highly expressed in lymphoid tissues in mice. 9, 31 The endogenous functions of Bfl-1 are largely unknown, due to difficulties with accomplishing targeted gene ablation in mouse models. Unlike the other anti-apoptotic members of the Bcl-2 family that have all been successfully ablated in mice, the mouse ortholog of Bfl-1 consists of a cluster of four replicated genes (i.e., four copies of the gene, termed A1a, A1b, A1c, and A1d). Thus, to the extent that the Bfl-1 inhibitory compounds described here cross-react with murine A1 orthologs, they may provide a useful tool for investigating the function of A1 proteins in mouse models.
The most potent of the Bfl-1 inhibitory compounds described here are only marginally active against the target protein in vitro, with approximately micromolar IC 50 values. Inhibiting (or mimicking as is the case here) proteinprotein interactions is a challenge for small molecules, especially in the case of Bcl-2 family proteins where the ligand binding site is large, accommodating BH3 peptides of ~16 amino acids in length. However, the ability to identify small compounds (molecular weight [MW] <500) that show micromolar activity bodes well for employing some of these compounds as a starting point for further optimization. Given the size of the BH3 peptide binding site, it is unlikely that extensive analoging on the sulfonylpyrimidine or chloromaleimide scaffolds will drive potency into the nanomolar level. Rather, by analogy to ABT-737 and ABT-263 (which have MW of ≈813-975 Daltons and yet possess excellent pharmacological properties 28 ), use of technologies such as "chemical fragment" screening by nuclear magnetic resonance (NMR), x-ray crystallography, or surface plasmon resonance (SPR) will likely be required to identify complementary chemical moieties that could be covalently linked onto the sulfonylpyrimidine or chloromaleimide scaffolds to increase the surface area of the BH3 peptide-binding pocket filled by the compounds.
In this report, we demonstrated that Bfl-1-binding compounds show activity in a mitochondrial assay that measures Bfl-1-mediated protection of these organelles. The advantage of this bioassay over a cell-based assay is that it avoids many of the variables that affect compound performance irrespective of target binding, such as cell membrane permeability, serum stability, and plasma protein binding. Interestingly, the sulfonylpyrimidine and chloromaleimide compounds showed different activity profiles in this assay, where sulfonylpyrimidine CID-1151859 induced release of SMAC from isolated mitochondria, whereas chloromaleimide compound CID-1180676 did not. Given that the exemplary chloromaleimide compound tested here was more potent against Bfl-1 by about 6-to 11-fold (depending on the assay method), the ability of the sulfonylpyrimidine to stimulate release of proteins from mitochondria cannot be explained by its Bfl-1 inhibitory activity. Thus, the sulfonylpyrimidine compound possesses a bioactivity separate from Bfl-1, although this bioactivity can be neutralized upon addition of Bfl-1 protein (but not Bcl-X L protein) to the mitochondria assay. Because the chloromaleimide did not induce SMAC release from mitochondria, we used recombinant active Bid (a pro-apoptotic Bcl-2 family protein) to stimulate protein release from mitochondria in vitro, demonstrating that recombinant Bfl-1 and Bcl-X L block the impact of Bid, with chloromaleimide CID-1180676 (also known as MLS-0053105 and ML041) (http://mli.nih.gov/ mli/mlp-probes/?dl_id=1289) neutralizing Bfl-1 but not Bcl-X L . Thus, we favor the chloromaleimide series as a starting point for future optimization campaigns.
